newsfilter
← Latest News
GlobeNewswire·

BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Enrollment complete in SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia Topline data expected in second half of 2025 intended to support